Prolonged prophylaxis in orthopedic surgery: insights from the United States
dc.contributor.author | Anderson, Frederick A. Jr. | |
dc.contributor.author | White, Kami | |
dc.date | 2022-08-11T08:08:09.000 | |
dc.date.accessioned | 2022-08-23T15:44:22Z | |
dc.date.available | 2022-08-23T15:44:22Z | |
dc.date.issued | 2002-08-17 | |
dc.date.submitted | 2011-11-03 | |
dc.identifier.citation | Semin Thromb Hemost. 2002 Aug;28 Suppl 3:43-6. <a href="http://dx.doi.org/10.1055/s-2002-34075">Link to article on publisher's site</a> | |
dc.identifier.issn | 0094-6176 (Linking) | |
dc.identifier.doi | 10.1055/s-2002-34075 | |
dc.identifier.pmid | 12232823 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14038/27297 | |
dc.description.abstract | The U.S. Hip and Knee Registry is a voluntary national registry of outcome data for hip and knee surgery. In total, 469 orthopedic surgeons from 325 hospitals reported data on 7677 patients who underwent total hip arthroplasty (THA) and 11,461 patients who underwent total knee arthroplasty (TKA). Data on patients enrolled between 1996 and 2000 indicate that 40% of THA patients and 42% of TKA patients received prophylaxis for a period of 8 to 21 days, including the in-hospital period. Prolonged prophylaxis for more than 21 days was used in 49% of THA patients and 44% of TKA patients. Moreover, year on year, data indicate that the percentage of patients who receive prophylaxis for longer than 21 days is gradually increasing. In 2000, 53% of THA patients and 47% of TKA patients received prophylaxis for longer than 21 days. | |
dc.language.iso | en_US | |
dc.relation | <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=12232823&dopt=Abstract">Link to Article in PubMed</a> | |
dc.relation.url | http://dx.doi.org/10.1055/s-2002-34075 | |
dc.subject | Aged | |
dc.subject | *Arthroplasty, Replacement, Hip | |
dc.subject | *Arthroplasty, Replacement, Knee | |
dc.subject | Bandages | |
dc.subject | Combined Modality Therapy | |
dc.subject | Drug Utilization | |
dc.subject | Female | |
dc.subject | Fibrinolytic Agents | |
dc.subject | Heparin, Low-Molecular-Weight | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Postoperative Complications | |
dc.subject | Postoperative Period | |
dc.subject | Pulmonary Embolism | |
dc.subject | Registries | |
dc.subject | Thrombosis | |
dc.subject | United States | |
dc.subject | Health Services Research | |
dc.subject | Orthopedics | |
dc.title | Prolonged prophylaxis in orthopedic surgery: insights from the United States | |
dc.type | Journal Article | |
dc.source.journaltitle | Seminars in thrombosis and hemostasis | |
dc.source.volume | 28 Suppl 3 | |
dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/cor_hipknee/1 | |
dc.identifier.contextkey | 2328947 | |
html.description.abstract | <p>The U.S. Hip and Knee Registry is a voluntary national registry of outcome data for hip and knee surgery. In total, 469 orthopedic surgeons from 325 hospitals reported data on 7677 patients who underwent total hip arthroplasty (THA) and 11,461 patients who underwent total knee arthroplasty (TKA). Data on patients enrolled between 1996 and 2000 indicate that 40% of THA patients and 42% of TKA patients received prophylaxis for a period of 8 to 21 days, including the in-hospital period. Prolonged prophylaxis for more than 21 days was used in 49% of THA patients and 44% of TKA patients. Moreover, year on year, data indicate that the percentage of patients who receive prophylaxis for longer than 21 days is gradually increasing. In 2000, 53% of THA patients and 47% of TKA patients received prophylaxis for longer than 21 days.</p> | |
dc.identifier.submissionpath | cor_hipknee/1 | |
dc.contributor.department | Center for Outcomes Research | |
dc.source.pages | 43-6 |